PA5-33691

antibody from Invitrogen Antibodies

Targeting: GPER1 CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR

Western blot (Recommended by provider)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-33691

Provider

Invitrogen Antibodies

Product name

GPR30 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Percent identity with other species by BLAST analysis: Human, Gorilla (100%) Monkey, Marmoset (88%).

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

50 µg

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.

Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C
Cancer medicine 2019 Dec;8(18):7705-7719

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of formalin-fixed paraffin-embedded human breast carcinoma using a GPR30 polyclonal antibody (Product # PA5-33691). Heat-induced antigen retrieval was performed prior to staining.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 GPER1 as proposed molecular mechanism of genistein in pancreatic cancer cells. A, A higher expression of GPER1 mRNA (>68 RSEM) is correlated with better overall survival (log-rank test, P = .019) in the TCGA cohort of pancreatic cancer patients (n = 175). B, GPER1 mRNA and (C) protein is expressed in both MiaPaCa2 and PANC1, and higher in PANC1. Protein is indicated at approximately 43 kDa, the erythroleukemia HEL and leukemic monocyte THP1 cell lines that have no mRNA evidence of GPER1 (per the http://www.proteinatlas.org ) were used as negative controls, and GAPDH was used as a loading control. D, Proposed molecular mechanism of genistein includes activation of the GPER1 and downstream proposed targets, based on RNA-seq analysis of treated MiaPaCa2 and PANC1 cells. E, Expression (FPKM values) of proposed genistein-targets upregulated upon co-treatment with genistein compared to gemcitabine monotreatment (FDR < 0.05) in MiaPaCa2 (left) and PANC1 (right)